Iron nanoparticle could light up MS brain inflammation on MRI
NCT ID NCT02511028
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tested whether ferumoxytol, an iron-based contrast agent, can help MRI scans better detect inflammation in the brains of people with multiple sclerosis (MS). Fourteen participants (some with MS, some healthy) received a single IV dose of ferumoxytol and had multiple 7-tesla MRI scans over six months. The goal was to see if the drug causes lasting changes in brain signals and whether it can highlight areas of inflammation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ferumoxytol (an iron-based contrast agent given by IV)
What this could lead to
If successful, ferumoxytol could become a new way to see inflammation in the brains of people with multiple sclerosis using MRI.
What could go wrong
This is a very small, early-phase study with only 14 participants. It is testing imaging, not treatment, so it won't directly improve MS symptoms. Ferumoxytol may cause long-lasting MRI signal changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States